Stock comparison
Evotec SE
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
EVO
Evotec SE
Market cap
$1.08B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | EVO | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 16F | 72B | LLY |
| Benjamin Graham | 24F | 86A | LLY |
| Philip Fisher | 22F | 86A | LLY |
| Peter Lynch | 14F | 74B | LLY |
| Joel Greenblatt | 0F | 78C | LLY |
| Charlie Munger | 22F | 85A | LLY |
| Terry Smith | 21F | 77C | LLY |
Side-by-side metrics
| Metric | EVO | LLY |
|---|---|---|
| Market cap | $1.08B | $1T |
| P/E (TTM) | - | 36.6x |
| EV/EBIT | - | 34.1x |
| ROIC (TTM) | -7.93% | 32.06% |
| Gross margin | 11.47% | 83.51% |
| Net margin | -26.02% | 34.98% |
| Revenue CAGR 5y | 5.21% | 23.17% |
| EPS CAGR 5y | - | 40.81% |
| Debt / Equity | 0.6x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
EVO leads on
- EV/EBIT-vs 34.1x+120%
- P/E (TTM)-vs 36.6x+113%
- Debt / Equity0.6xvs 1.4x+60%
LLY leads on
- Net margin34.98%vs -26.02%+174%
- ROIC (TTM)32.06%vs -7.93%+125%
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $1.08B+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.